Article | May 15, 2024

Navigating Audit Trail Data Regulations And Accessibility Changes

By James Stringer

GettyImages-1173740564 data management

Data is the cornerstone of clinical trials, underpinning critical decisions about therapies and trial performance. It highlights recruitment speed and drug supply management and is subject to rigorous regulatory scrutiny. The versatile nature of data means its utility varies based on the user's needs.

In a highly regulated industry, new guidelines continually emerge while existing ones gain prominence as the sector evolves. Regulatory bodies like the UK's MHRA, the EU's EMA, and the US's FDA mandate documented, human-readable, and regularly reviewed audit trails.

The EMA's March 2023 guidance emphasizes the investigator’s responsibility for audit trail reviews and data ownership, acknowledging the complexity this poses for data providers. Despite the longstanding nature of these regulations, a complete industry-wide solution remains elusive.

This raises the question: How can proprietary audit trail data, stored in proprietary formats, be effectively accessed and utilized?

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader